| Document |
Document Title |
|
WO/2004/080962A1 |
The invention relates to novel 2,4,6-phenyl substituted cyclic ketoenols of formula (I), in which W, X, Y and CKE are defined as cited in the description, in addition to several methods for their production and to their use as pesticides...
|
|
WO/2004/080976A1 |
Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X NRX then n is 1 or 2 and if X = CRXRY then n is 1; RX is selected from the group consisting of H...
|
|
WO/2004/076420A1 |
A compound represented by the following formula (I): (I) [wherein X1 represents oxygen, etc.; X2 represents oxygen, etc.; R1 represents an alkylsulfonyl or another group on the ring A; R2 represents, e.g., C3-7 cyclic alkyl optionally su...
|
|
WO/2004/074259A1 |
The invention provides compounds of Formula (I) that bind to GABAA receptors. In the above formula, variables are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are parti...
|
|
WO/2004/073634A2 |
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
|
|
WO/2004/063163A1 |
Compounds of Formula (I) wherein R1, R2 R3, R4, R5, R6, and X are as defiend herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods o...
|
|
WO/2004/060860A2 |
The invention relates to a method for inhibiting the replication of herpes viruses, to methods for identifying compounds that inhibit the replication of herpes viruses with this method, to compounds with activity directed against herpes ...
|
|
WO/2004/058729A1 |
Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4:, wherein R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group.
|
|
WO/2004/058723A1 |
A fungicidally active compound of formula (I): where Het is a substituted 5- or 6-membered heterocyclic ring; R1 is hydrogen, formyl, CO-C1-4 alkyl, COO-C1-4 alkyl, C1-4 alkoxy(C1-4)alkylene, CO-C1-4 alkylenoxy(C1-4)alkyl, propargyl or a...
|
|
WO/2004/056751A1 |
Compounds of formula (I) have antibacterial activity, wherein Q represents -N(OH)CH(=O) or -C(=O)NH(OH); Y represents -C(=O)-, - C(=S)-, -S(=O)-, or -SO2-; R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more hal...
|
|
WO/2004/056764A1 |
The present invention provides HIV aspartyl protease inhibitors of the formula (I); and when the compound of formula (I) comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be...
|
|
WO/2004/056797A1 |
The present invention relates to compounds of the general formula (II) and salts and physiologically functional derivatives thereof, for the use as a medicament.
|
|
WO/2004/056746A1 |
The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein A is a non-aromatic ring system containing 4 to 8 carbon atoms, wherein the ring system comprises...
|
|
WO/2004/056747A1 |
The present invention relates to compounds of the general formula (I), or salts or isomeres thereof, wherein A is a 4-8 membered non-aromatic ring system, to compounds of the general formula (II), or salts or isomeres thereof, wherein A ...
|
|
WO/2004/052866A1 |
A 3-phenyl-cinnoline homologue or a physiologically acceptable salt thereof; and a cytostatic agent or antitumor agent comprising the same as an active constituent.
|
|
WO/2004/050657A2 |
This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising...
|
|
WO/2004/050638A1 |
Compounds of formula (I) have antibacterial activity; wherein Q represents a radical of formula -N(OH)CH(=O) or formula -C(=O)NH(OH); Y represents -C(=O)-, -C(=S)-, -S(=O)-, or -SO2-; R1 represents hydrogen, Cl-C6 alkyl or Cl-C6 alkyl su...
|
|
WO/2004/046117A1 |
The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl (C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-a...
|
|
WO/2004/046130A1 |
The present invention relates to novel pyridazinone derivatives of the general formula (I), wherein A is A1 or A2; O A1= ˜,N˜R A2= NH R H O R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl (C1-C10-alkyl)-, hetero...
|
|
WO/2004/043458A1 |
Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for ...
|
|
WO/2004/039780A1 |
The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive...
|
|
WO2004026305A9 |
A compound of the formula (I) wherein the variables X1 to X10, R<1> to R<7> including R<3'>, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, us...
|
|
WO/2004/037800A1 |
The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
|
WO/2004/033444A1 |
The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such c...
|
|
WO/2004/032861A2 |
The present invention is directed to compounds having the formula (I) useful in treating inflammatory and immune diseases, in which K is O or S; Q is -C(=O)- or optionally substituted C1-4alkylene; Ar is optionally-substituted aryl or he...
|
|
WO/2004/029183A1 |
Disclosed herein is a composition comprising: (A) a lubricant, and; (B) at least one alkyl succinhydrazide compound of the formula: (I); wherein R1 is selected from the group consisting of linear or branched alkyl, alkenyl, alkaryl, alky...
|
|
WO2003099284B1 |
Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes,...
|
|
WO/2004/024158A1 |
5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylam
ino]-propylamino]-3-(2H)-pyridazinone of the Formula (I) and salts thereof are metabolic modulators and can be used for the treatment or prevention of heart failure and ischaem...
|
|
WO/2004/022563A1 |
The invention concerns novel heterocyclic compounds of formula (1), and their salts with a base or an acid. The invention also concerns the method as well as the intermediates for preparing said compounds, and their use as medicines, in ...
|
|
WO/2004/021989A2 |
Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention f...
|
|
WO/2004/022054A1 |
Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention f...
|
|
WO/2004/022523A2 |
The present invention relates to compounds of formula (AA), (I) and (X), useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment ...
|
|
WO/2004/014892A1 |
This invention provides compounds defined by Formula (I) or a pharmaceutically acceptable salt thereof, wherein R', Q, D, V', m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprisi...
|
|
WO/2004/014866A1 |
This invention provides compounds defined by Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, Q, Y, R2, R3, R4, R5, and n are as defined in the specification. The invention also provides pharmaceutical compositions...
|
|
WO/2004/014865A1 |
A class of 4-phenylpyridazine derivatives of Formula (I), being selective ligands for GABAA receptors, in particular having high affinity for the &agr 2 and/or &agr 3 and or &agr 5 subunit thereof, are accordingly of benefit in the treat...
|
|
WO/2004/011410A1 |
Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11$g(b)HSD1 are described.
|
|
WO/2004/011441A1 |
A compound of formula (I) wherein X is S or O and A, R1-R4, n, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a 'Pyridazinylpiperazine Compound'), compositions comprising a Pyridazinylpiperazine Compound, and ...
|
|
WO/2004/009561A1 |
Disclosed are 3-heterocyclyl substituted benzoic acid derivatives of general formula (I), in which the variables R1 to R8 and X have the meanings indicated in claim 1, and the use thereof as herbicides or for desiccating/defoliating plants.
|
|
WO/2004/007457A2 |
Selected compounds of formula (IV) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives ...
|
|
WO/2004/005407A2 |
The invention concerns the use as direct dyeing agent of at least one tetra-azapentamethine compound, a dyeing composition comprising at least such a compound, as well as a method for dyeing keratinous fibers, in particular human keratin...
|
|
WO/2004/002983A2 |
A compound of formula (I): wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a 'Cyanoiminopiperazine Compound'), cornposition, comprising an effective amount of a Cyanoiminopiperazine Compo...
|
|
WO/2003/106431A2 |
The invention concerns a compound of general formula (I). The invention also concerns combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions and methods for preparing same.
|
|
WO/2003/104205A1 |
The invention relates to aryloximes of formula (I), wherein R1, R2, R3, X and B have the meanings as cited in Claim No. 1. These aryloximes act as phosphodiesterase IV inhibitors and can be used for treating osteoporosis, tumors, cachexi...
|
|
WO/2003/104206A2 |
Compounds of formula (I), wherein Q is a group, (II), (III), (IV), (V), (VI) or (VII); Z is =N-, (VIII) or =C(R1)-; n is 0, 1, 2, 3 or 4; R1 and R2 are as defined in claim 1; R3 and R4 are each independently of the other hydrogen, haloge...
|
|
WO/2003/104204A1 |
Disclosed are pyridazine derivatives of formula (I), which act as phosphodiesterase IV inhibitors and can be used for treating osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, ...
|
|
WO/2003/101442A1 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
WO/2003/099773A1 |
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of ...
|
|
WO/2003/099776A1 |
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...
|
|
WO/2003/097582A2 |
Benzonitrites and benzimidates represent important intermediates and starting materials, which are typically not commercially available. The present invention discloses a facile synthesis for 2,4-dihydroxybenzonitrile, and ethers and die...
|
|
WO/2003/097586A1 |
This invention is directed to vanilloid receptor VR1 ligands of formula (1). More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment an...
|
